Transcriptional response to fluconazole and amphotericin B in Candida albicans biofilms

Research in Microbiology

Volumn 161, Issue 4, 2010, Pages 284-292

  Nailis, Heleen ^a   Vandenbosch, Davy ^a   Deforce, Dieter ^a   Nelis, Hans J ^a   Coenye, Tom ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

Amphotericin B; Biofilms; Candida albicans; Fluconazole; Gene expression; Resistance; RT quantitative PCR

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; BETA 1,6 GLUCAN; ERGOSTEROL; ERGOSTEROL 1; ERGOSTEROL 11; ERGOSTEROL 25; ERGOSTEROL 3; FLUCONAZOLE; FUNGAL PROTEIN; KRE1 PROTEIN; SKN1 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BIOFILM; BIOSYNTHESIS; CANDIDA ALBICANS; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; IN VITRO STUDY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TREATMENT RESPONSE; UPREGULATION;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; BIOFILMS; CANDIDA ALBICANS; DRUG RESISTANCE, FUNGAL; FLUCONAZOLE; FUNGAL PROTEINS; GENE EXPRESSION REGULATION, FUNGAL; TRANSCRIPTION, GENETIC;

CANDIDA ALBICANS;

EID: 77953621452     PISSN: 09232508     EISSN: 17697123     Source Type: Journal    
DOI: 10.1016/j.resmic.2010.02.004     Document Type: Article

References (38)

1. Al-Dhaheri R.S., Douglas L.J. Absence of amphotericin B-tolerant persister cells in biofilms of some Candida species. Antimicrob. Agents Chemother. 2008, 52:1884-1887.
2. Brajtburg J., Powderly W.G., Kobayashi G.S., Medoff G. Amphotericin B: current understanding of mechanisms of action. Antimicrob. Agents Chemother. 1990, 34:183-188.
3. Chandra J., Kuhn D.M., Mukherjee P.K., Hoyer L.L., McCormick T., Ghannoum M.A. Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J. Bacteriol. 2001, 183:5385-5394.
4. Cuenca-Estrella M., Moore C.B., Barchiesi F., Bille J., Chryssanthou E., Denning D.W., AFST Subcommittee of the European Committee on Antimicrobial Susceptibility Testing, et al. Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). Clin. Microbiol. Infect. 2003, 9:467-474.
5. De Backer M.D., Ilyina T., Ma X.J., Vandonink S., Luyten W.H., Vanden Bossche H. Genomic profiling of the response of Candida albicans to itraconazole treatment using a DNA microarray. Antimicrob. Agents Chemother. 2001, 45:1660-1670.
6. Douglas L.J. Candida biofilms and their role in infection. Trends Microbiol. 2003, 11:30-36.
7. Ellis D. Amphotericin B: spectrum and resistance. J. Antimicrob. Chemother. 2002, 49:7-10.
8. Franz R., Kelly S.L., Lamb D.C., Kelly D.E., Ruhnke M., Morschhäuser J. Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains. Antimicrob. Agents Chemother. 1998, 42:3065-3072.
9. Gale E.F. Nature and development of phenotypic resistance to amphotericin B in Candida albicans. Adv. Microb. Physiol. 1986, 27:277-320.
10. Hawser S.P., Douglas L.J. Resistance of Candida albicans biofilms to antifungal agents in vitro. Antimicrob. Agents Chemother. 1995, 39:2128-2131.
11. Henry K.W., Nickels J.T., Edlind T.D. Upregulation of ERG genes in Candida species by azoles and other sterol biosynthesis inhibitors. Antimicrob. Agents Chemother. 2000, 44:2693-2700.
12. Hernáez M.L., Gil C., Pla J., Nombela C. Induced expression of the Candida albicans multidrug resistance gene CDR1 in response to fluconazole and other antifungals. Yeast 1998, 14:517-526.
13. Kelly S.L., Arnoldi A., Kelly D.E. Molecular genetic analysis of azole antifungal mode of action. Biochem. Soc. Trans. 1993, 21:1034-1038.
14. Khot P.D., Suci P.A., Miller R.L., Nelson R.D., Tyler B.J. A small subpopulation of blastospores in Candida albicans biofilms exhibit resistance to amphotericin B associated with differential regulation of ergosterol and bèta-1,6-glucan pathway genes. Antimicrob. Agents Chemother. 2006, 50:3708-3716.
15. Kuhn D.M., Ghannoum M.A. Candida biofilm: antifungal resistance and emerging therapeutic options. Curr. Opin. Investig. Drugs 2004, 5:186-197.
16. Kuhn D.M., George T., Chandra J., Mukherjee P.K., Ghannoum M.A. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob. Agents Chemother. 2002, 46:1773-1780.
17. Kumamoto C.A. Candida biofilms. Curr. Opin. Microbiol. 2002, 5:608-611.
18. LaFleur M.D., Kumamoto C.A., Lewis K. Candida albicans biofilms produce antifungal-tolerant persister cells. Antimicrob. Agents Chemother. 2006, 50:3839-3846.
19. Lepak A., Nett J., Lincoln L., Marchillo K., Andes D. Time course of microbiologic outcome and gene expression in Candida albicans during and following in vitro and in vivo exposure to fluconazole. Antimicrob. Agents Chemother. 2006, 50:1311-1319.
20. Liu T.T., Lee R.E., Barker K.S., Lee R.E., Wei L., Homayouni R., et al. Genome-wide expression profiling of the response to azole, polyene, echinocandin, and pyrimidine antifungal agents in Candida albicans. Antimicrob. Agents Chemother. 2005, 49:2226-2236.
21. Lopez-Ribot J.L., McAtee R.K., Lee L.N., Kirkpatrick W.R., White T.C., Sanglard D., et al. Distinct patterns of gene expression associated with development of fluconazole resistance in serial Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob. Agents Chemother. 1998, 42:2932-2937.
22. Mateus C., Crow S.A., Ahearn D.G. Adherence of Candida albicans to silicone induces immediate enhanced tolerance to fluconazole. Antimicrob. Agents Chemother. 2004, 48:3358-3366.
23. Mio T., Yamada-Okabe T., Yabe T., Nakajima T., Arisawa M., Yamada-Okabe H. Isolation of the Candida albicans homologs of Saccharomyces cerevisiae KRE6 and SKN1: expression and physiological function. J. Bacteriol. 1997, 179:2363-2372.
24. Mukherjee P.K., Chandra J., Kuhn D.M., Ghannoum M.A. Mechanisms of fluconazole resistance in Candida albicans biofilms: phase-specific role of efflux pumps and membrane sterols. Infect. Immun. 2003, 71:4333-4340.
25. Nailis H., Coenye T., Van Nieuwerburgh F., Deforce D., Nelis H.J. Development and evaluation of different normalization strategies for gene expression studies in Candida albicans biofilms by real-time PCR. BMC Mol. Biol. 2006, 7:25.
26. Nailis H., Vandenbroucke R., Tilleman K., Deforce D., Nelis H., Coenye T. Monitoring ALS1 and ALS3 gene expression during in vitro Candida albicans biofilm formation under continuous flow conditions. Mycopathologia 2009, 167:9-17.
27. Odds F.C. Meeting Candida and Candidiosis 1988, Bailliere Tindall, London, UK. second ed.
28. Pappas P.G., Rex J.H., Sobel J.D., Filler S.G., Dismukes W.E., Walsh T.J., et al. Infectious Disease Society of Amerika; Guidelines for treatment of candidiasis. Clin. Infect. Dis. 2004, 38:161-189.
29. Ponton J., Quindos G., Arilla M.C., Mackenzie D.W. Simplified adsorption method for detection of antibodies to Candida albicans germ tubes. J. Clin. Microbiol. 1994, 32:217-219.
30. Ramage G., Bachmann S., Patterson T.F., Wickes B.L., López-Ribot J.L. Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms. J. Antimicrob. Chemother. 2002, 49:973-980.
31. Richardson K. The discovery and profile of fluconazole. J. Chemother. 1990, 2:51-54.
32. Rogers P.D., Barker K.S. Genome-wide expression profile analysis reveals coordinately regulated genes associated with stepwise acquisition of azole resistance in Candida albicans clinical isolates. Antimicrob. Agents Chemother. 2003, 47:1220-1227.
33. Sanglard D. Resistance of human fungal pathogens to antifungal drugs. Curr. Opin. Microbiol. 2002, 5:379-385.
34. Warnock D.W. Amphotericin B: an introduction. J. Antimicrob. Chemother. 1991, 28:27-38.
35. White T.C. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 1997, 41:1482-1487.
36. White T.C., Marr K.A., Bowden R.A. Clinical, cellular and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev. 1998, 11:382-402.
37. White T.C., Holleman S., Dy F., Mirels L.F., Stevens D.A. Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob. Agents Chemother. 2002, 46:1704-1713.
38. Zhao X., Daniels K.J., Oh S.H., Green C.B., Yeater K.M., Soll D.R., et al. Candida albicans Als3p is required for wild-type biofilm formation on silicone elastomer surfaces. Microbiology 2006, 152:2287-2299.